SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 7th, 2013 • Opexa Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 7th, 2013 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of February 7, 2013, between Opexa Therapeutics, Inc., a Texas corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
EXHIBIT 10.1 SECOND AMENDED AND RESTATED LICENSE AGREEMENT This Second Amended and Restated License Agreement ("Agreement"), effective this 31st day of July, 2007 is between the University of Chicago, an Illinois not-for-profit corporation...License Agreement • August 3rd, 2007 • Opexa Therapeutics, Inc. • Pharmaceutical preparations • Illinois
Contract Type FiledAugust 3rd, 2007 Company Industry Jurisdiction
UNDERWRITING AGREEMENT between OPEXA THERAPEUTICS, INC. and AEGIS CAPITAL CORP., as Representative of the Several UnderwritersUnderwriting Agreement • July 22nd, 2013 • Opexa Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 22nd, 2013 Company Industry JurisdictionThe undersigned, Opexa Therapeutics, Inc., a corporation formed under the laws of the State of Texas (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Opexa Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
TERMS -----Warrant Agreement • April 15th, 2005 • Pharmafrontiers Corp • Pharmaceutical preparations
Contract Type FiledApril 15th, 2005 Company Industry
BY AND AMONGStock Purchase Agreement • June 4th, 2004 • Sportan United Industries Inc • Sporting & athletic goods, nec • Texas
Contract Type FiledJune 4th, 2004 Company Industry Jurisdiction
RECITALSPurchase Agreement • April 18th, 2006 • PharmaFrontiers Corp. • Pharmaceutical preparations • New York
Contract Type FiledApril 18th, 2006 Company Industry Jurisdiction
RECITALS:Registration Rights Agreement • July 19th, 2005 • Pharmafrontiers Corp • Pharmaceutical preparations
Contract Type FiledJuly 19th, 2005 Company Industry
RECITALS:Registration Rights Agreement • July 19th, 2005 • Pharmafrontiers Corp • Pharmaceutical preparations
Contract Type FiledJuly 19th, 2005 Company Industry
WHEREAS, the Company desires to employ the Executive to have the benefits of (his/his/her) expertise and knowledge. The Executive, in turn, desires employment with the Company. The parties, therefore, enter into this Agreement to establish the terms...Employment Agreement • June 4th, 2004 • Sportan United Industries Inc • Sporting & athletic goods, nec • Texas
Contract Type FiledJune 4th, 2004 Company Industry Jurisdiction
EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the "Agreement") is made and entered into as of this 11th day of April, 2006 by and among PharmaFrontiers Corp., a Texas corporation (the "Company"), and the "Investors"...Registration Rights Agreement • April 18th, 2006 • PharmaFrontiers Corp. • Pharmaceutical preparations • New York
Contract Type FiledApril 18th, 2006 Company Industry Jurisdiction
INDEMNIFICATION AGREEMENTIndemnification Agreement • July 19th, 2017 • Opexa Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJuly 19th, 2017 Company Industry JurisdictionTHIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of April 21, 2016 between Acer Therapeutics Inc., a Delaware corporation (the “Company”), and Luc Marengere (“Indemnitee”).
RECITALS:Securities Purchase Agreement • July 19th, 2005 • Pharmafrontiers Corp • Pharmaceutical preparations • New York
Contract Type FiledJuly 19th, 2005 Company Industry Jurisdiction
Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement entered into September 30, 2000 ("Agreement") is by and between, SPORTAN UNITED INDUSTRIES, INC., a Texas corporation ("Company") and THOMAS C. PRITCHARD, an individual ("Consultant"). W I T...Consulting Agreement • October 20th, 2000 • Sportan United Industries Inc • Sporting & athletic goods, nec • Texas
Contract Type FiledOctober 20th, 2000 Company Industry Jurisdiction
LICENSE AGREEMENT BY AND BETWEEN PHARMAFRONTIERS CORP.License Agreement • February 9th, 2006 • PharmaFrontiers Corp. • Pharmaceutical preparations • Texas
Contract Type FiledFebruary 9th, 2006 Company Industry Jurisdiction
Amended and Restated Sales AgreementSales Agreement • March 18th, 2020 • Acer Therapeutics Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 18th, 2020 Company Industry JurisdictionAcer Therapeutics Inc., a Delaware corporation (the “Company”) and Roth Capital Partners, LLC (“Roth”) are parties to that certain Sales Agreement dated November 9, 2018 (the “Original Sales Agreement”). The Company and Roth, together with JonesTrading Institutional Services LLC (“JonesTrading” and together with Roth, the “Agents”) desire to amend and restate the Original Sales Agreement with this agreement (the “Agreement”), and hereby agree as follows:
PRE-FUNDED COMMON STOCK PURCHASE WARRANT ACER THERAPEUTICS INC.Pre-Funded Common Stock Purchase Warrant • March 22nd, 2023 • Acer Therapeutics Inc. • Pharmaceutical preparations
Contract Type FiledMarch 22nd, 2023 Company IndustryTHIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Acer Therapeutics Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 30th, 2020 • Acer Therapeutics Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 30th, 2020 Company Industry JurisdictionTHIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April 30, 2020, by and between ACER THERAPEUTICS INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
WARRANTWarrant Agreement • April 18th, 2006 • PharmaFrontiers Corp. • Pharmaceutical preparations • California
Contract Type FiledApril 18th, 2006 Company Industry Jurisdiction
COMMON STOCK PURCHASE WARRANT OPEXA THERAPEUTICS, INC.Common Stock Purchase Warrant • February 7th, 2013 • Opexa Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 7th, 2013 Company IndustryTHISCOMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after February __, 2013(the “Initial Exercise Date”) and on or prior to the close of business on the four (4)year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Opexa Therapeutics, Inc., a Texas corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT ACER THERAPEUTICS INC.Securities Agreement • March 22nd, 2023 • Acer Therapeutics Inc. • Pharmaceutical preparations
Contract Type FiledMarch 22nd, 2023 Company IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until [_______________]1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Acer Therapeutics Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
UNDERWRITING AGREEMENT between OPEXA THERAPEUTICS, INC. and AEGIS CAPITAL CORP., as Representative of the Several UnderwritersUnderwriting Agreement • December 18th, 2013 • Opexa Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledDecember 18th, 2013 Company Industry JurisdictionThe undersigned, Opexa Therapeutics, Inc., a corporation formed under the laws of the State of Texas (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus (as hereinafter defined) as being subsidiaries or affiliates of Opexa Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
EXHIBIT 10.4 SECOND AMENDMENT TO AMENDED AND RESTATED LICENSE AGREEMENT This Second Amendment to Amended and Restated License Agreement ("Second Amendment") effective this _______ day of April, 2006 is between the University of Chicago, an Illinois...License Agreement • April 18th, 2006 • PharmaFrontiers Corp. • Pharmaceutical preparations
Contract Type FiledApril 18th, 2006 Company Industry
PURCHASE AGREEMENTPurchase Agreement • April 30th, 2020 • Acer Therapeutics Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledApril 30th, 2020 Company Industry JurisdictionTHIS PURCHASE AGREEMENT (the “Agreement”), dated as of April 30, 2020, by and between ACER THERAPEUTICS INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 22nd, 2023 • Acer Therapeutics Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 22nd, 2023 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of March 21, 2023, between Acer Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
CONFIDENTIAL Neil K. Warma President & CEO Opexa Therapeutics, Inc.Placement Agent Agreement • December 10th, 2009 • Opexa Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledDecember 10th, 2009 Company Industry Jurisdiction
ANDAgreement and Plan of Reorganization • October 8th, 2004 • Pharmafrontiers Corp • Pharmaceutical preparations • Texas
Contract Type FiledOctober 8th, 2004 Company Industry Jurisdiction
[STATE SEAL APPEARS HERE] ----------- NUMBER SHARES ----------- INCORPORATED UNDER THE LAWS OF THE STATE OF ----------- 20 TEXAS ----------- ----------- ----------- -----------Shareholder Agreements • March 8th, 1999 • Sportan United Industries Inc
Contract Type FiledMarch 8th, 1999 CompanyThis Certificate that ______________________________ is the owner of ___________________________________________________ fully paid and non-assessable Shares of the above Corporation transferable only on the books of the Corporation by the holder hereof in person or by duly authorized Attorney upon surrender of this Certificate properly endorsed.
PLACEMENT AGENCY AGREEMENT February 7, 2013Placement Agency Agreement • February 7th, 2013 • Opexa Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 7th, 2013 Company Industry Jurisdiction
Exhibit 99.4 LEASE TERMINATION AGREEMENT This Lease Termination Agreement ("Agreement") is made and entered into effective as of the 13th day of January, 2005 by and between PHARMAFRONTIERS CORP., Assignee of OPEXA PHARMACEUTICALS, INC., ("Tenant")...Lease Termination Agreement • February 4th, 2005 • Pharmafrontiers Corp • Pharmaceutical preparations • Texas
Contract Type FiledFebruary 4th, 2005 Company Industry Jurisdiction
FORM OF OPEXA THERAPEUTICS, INC. DEALER-MANAGER AGREEMENTDealer-Manager Agreement • February 24th, 2015 • Opexa Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 24th, 2015 Company Industry Jurisdiction
ARTICLE 1 TERMS OF EMPLOYMENTEmployment Agreement • February 7th, 2001 • Sportan United Industries Inc • Sporting & athletic goods, nec
Contract Type FiledFebruary 7th, 2001 Company Industry
RECITALSLicense Agreement • November 1st, 2006 • Opexa Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 1st, 2006 Company Industry
4,146,500 Units par value $0.01 OPEXA THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 8th, 2011 • Opexa Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 8th, 2011 Company Industry Jurisdiction
OPEXA THERAPEUTICS, INC. DOCS® ATM financing facility Shares of Common Stock, $0.01 par value SALES AGREEMENT September 6, 2012Sales Agreement • September 7th, 2012 • Opexa Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 7th, 2012 Company Industry JurisdictionTHIS SALES AGREEMENT (the “Agreement”) dated as of September 6, 2012 between Brinson Patrick Securities Corporation, having its principal office at 1515 Broadway, 11th Floor, New York, New York 10036 (the “Sales Manager”) and Opexa Therapeutics, Inc., a corporation organized and existing under the laws of the State of Texas (the “Company”).
THIRD AMENDMENT TO CREDIT AGREEMENTCredit Agreement • May 15th, 2023 • Acer Therapeutics Inc. • Pharmaceutical preparations
Contract Type FiledMay 15th, 2023 Company IndustryTHIS THIRD AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of May 12, 2023, is entered into by and among ACER THERAPEUTICS INC., a Delaware corporation (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively “Lenders”) and SWK FUNDING LLC, a Delaware limited liability company, in its capacity as administrative agent for the other Lenders (in such capacity, “Agent”).